Literature DB >> 29461978

Surface receptor Toso controls B cell-mediated regulation of T cell immunity.

Jinbo Yu1,2, Vu Huy Hoang Duong1,2, Katrin Westphal1,2, Andreas Westphal1,2, Abdulhadi Suwandi3, Guntram A Grassl3, Korbinian Brand2, Andrew C Chan4, Niko Föger1,2, Kyeong-Hee Lee1,2.   

Abstract

The immune system is tightly controlled by regulatory processes that allow for the elimination of invading pathogens, while limiting immunopathological damage to the host. In the present study, we found that conditional deletion of the cell surface receptor Toso on B cells unexpectedly resulted in impaired proinflammatory T cell responses, which led to impaired immune protection in an acute viral infection model and was associated with reduced immunopathological tissue damage in a chronic inflammatory context. Toso exhibited its B cell-inherent immunoregulatory function by negatively controlling the pool of IL-10-competent B1 and B2 B cells, which were characterized by a high degree of self-reactivity and were shown to mediate immunosuppressive activity on inflammatory T cell responses in vivo. Our results indicate that Toso is involved in the differentiation/maintenance of regulatory B cells by fine-tuning B cell receptor activation thresholds. Furthermore, we showed that during influenza A-induced pulmonary inflammation, the application of Toso-specific antibodies selectively induced IL-10-competent B cells at the site of inflammation and resulted in decreased proinflammatory cytokine production by lung T cells. These findings suggest that Toso may serve as a novel therapeutic target to dampen pathogenic T cell responses via the modulation of IL-10-competent regulatory B cells.

Entities:  

Keywords:  Adaptive immunity; B cells; Immunology; Inflammation; Tolerance

Mesh:

Substances:

Year:  2018        PMID: 29461978      PMCID: PMC5919877          DOI: 10.1172/JCI97280

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  63 in total

Review 1.  Autoreactivity by design: innate B and T lymphocytes.

Authors:  A Bendelac; M Bonneville; J F Kearney
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

2.  Class switching and consecutive loss of dsDNA-reactive B1a B cells from the peritoneal cavity during murine lupus development.

Authors:  Philipp Enghard; Jens Y Humrich; Vantrung T Chu; Erwin Grussie; Falk Hiepe; Gerd-Rüdiger Burmester; Andreas Radbruch; Claudia Berek; Gabriela Riemekasten
Journal:  Eur J Immunol       Date:  2010-06       Impact factor: 5.532

3.  Toso regulates the balance between apoptotic and nonapoptotic death receptor signaling by facilitating RIP1 ubiquitination.

Authors:  Xuan-Hung Nguyen; Philipp A Lang; Karl S Lang; Dieter Adam; Gulnar Fattakhova; Niko Föger; Mohammad Azhar Kamal; Patricia Prilla; Sabine Mathieu; Christina Wagner; Tak Mak; Andrew C Chan; Kyeong-Hee Lee
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

4.  Toso regulates differentiation and activation of inflammatory dendritic cells during persistence-prone virus infection.

Authors:  P A Lang; A Meryk; A A Pandyra; D Brenner; A Brüstle; H C Xu; K Merches; F Lang; V Khairnar; P Sharma; P Funkner; M Recher; N Shaabani; G S Duncan; V Duhan; B Homey; P S Ohashi; D Häussinger; P A Knolle; N Honke; T W Mak; K S Lang
Journal:  Cell Death Differ       Date:  2014-09-26       Impact factor: 15.828

5.  TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation.

Authors:  Bérengère Vire; Alexandre David; Adrian Wiestner
Journal:  J Immunol       Date:  2011-09-09       Impact factor: 5.422

Review 6.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

7.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Authors:  Paul A Blair; Lina Yassin Noreña; Fabian Flores-Borja; David J Rawlings; David A Isenberg; Michael R Ehrenstein; Claudia Mauri
Journal:  Immunity       Date:  2010-01-14       Impact factor: 31.745

8.  Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis.

Authors:  Guntram A Grassl; Yanet Valdez; Kirk S B Bergstrom; Bruce A Vallance; B Brett Finlay
Journal:  Gastroenterology       Date:  2008-01-09       Impact factor: 22.682

9.  B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity.

Authors:  Lily I Pao; Kong-Peng Lam; Joel M Henderson; Jeffery L Kutok; Marat Alimzhanov; Lars Nitschke; Matthew L Thomas; Benjamin G Neel; Klaus Rajewsky
Journal:  Immunity       Date:  2007-06-28       Impact factor: 31.745

10.  Identity of the elusive IgM Fc receptor (FcmuR) in humans.

Authors:  Hiromi Kubagawa; Satoshi Oka; Yoshiki Kubagawa; Ikuko Torii; Eiji Takayama; Dong-Won Kang; G Larry Gartland; Luigi F Bertoli; Hiromi Mori; Hiroyuki Takatsu; Toshio Kitamura; Hiroshi Ohno; Ji-Yang Wang
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

View more
  10 in total

Review 1.  B Cell Activation and Response Regulation During Viral Infections.

Authors:  Jonathan H Lam; Fauna L Smith; Nicole Baumgarth
Journal:  Viral Immunol       Date:  2020-04-23       Impact factor: 2.257

Review 2.  B Cell Responses: Cell Interaction Dynamics and Decisions.

Authors:  Jason G Cyster; Christopher D C Allen
Journal:  Cell       Date:  2019-04-18       Impact factor: 41.582

Review 3.  Immunosuppressive Mechanisms of Regulatory B Cells.

Authors:  Diego Catalán; Miguel Andrés Mansilla; Ashley Ferrier; Lilian Soto; Kristine Oleinika; Juan Carlos Aguillón; Octavio Aravena
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 7.561

Review 4.  Functional Roles of the IgM Fc Receptor in the Immune System.

Authors:  Hiromi Kubagawa; Kazuhito Honjo; Naganari Ohkura; Shimon Sakaguchi; Andreas Radbruch; Fritz Melchers; Peter K Jani
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

Review 5.  Role of the IgM Fc Receptor in Immunity and Tolerance.

Authors:  Jun Liu; Ying Wang; Ermeng Xiong; Rongjian Hong; Qing Lu; Hiroshi Ohno; Ji-Yang Wang
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

6.  Mapping of the binding site for FcμR in human IgM-Fc.

Authors:  Rosemary A Nyamboya; Brian J Sutton; Rosaleen A Calvert
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2019-08-23       Impact factor: 3.036

7.  Identification of Amino Acid Residues in Human IgM Fc Receptor (FcµR) Critical for IgM Binding.

Authors:  Christopher M Skopnik; Khlowd Al-Qaisi; Rosaleen A Calvert; Philipp Enghard; Andreas Radbruch; Brian J Sutton; Hiromi Kubagawa
Journal:  Front Immunol       Date:  2021-01-27       Impact factor: 7.561

8.  Questioning whether IgM Fc receptor (FcµR) is expressed by innate immune cells.

Authors:  Christopher M Skopnik; René Riedel; Richard K Addo; Gitta Anne Heinz; Frederik Heinrich; Kazuhito Honjo; Pawel Durek; Philipp Enghard; Mir-Farzin Mashreghi; Andreas Radbruch; Hiromi Kubagawa
Journal:  Nat Commun       Date:  2022-07-11       Impact factor: 17.694

Review 9.  Antibody-independent functions of B cells during viral infections.

Authors:  Vinit Upasani; Izabela Rodenhuis-Zybert; Tineke Cantaert
Journal:  PLoS Pathog       Date:  2021-07-22       Impact factor: 6.823

10.  WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine.

Authors:  Shouq Alzaaqi; Norifumi Naka; Kenichiro Hamada; Naoki Hosen; Mizuki Kanegae; Hidetatsu Outani; Mayuko Adachi; Rin Imanishi; Eiichi Morii; Miki Iwai; Jun Nakata; Fumihiro Fujiki; Soyoko Morimoto; Hiroko Nakajima; Sumiyuki Nishida; Akihiro Tsuboi; Yoshihiro Oka; Haruo Sugiyama; Yusuke Oji
Journal:  Oncol Lett       Date:  2022-01-03       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.